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Pregnancy Complications as Markers
for Subsequent Maternal Cardiovascular Disease:
Validation of a Maternal Recall Questionnaire
Ebony Boyce Carter, MD, MPH,1,* Jennifer J. Stuart, MSc,2,3,* Leslie V. Farland, MSc,2
Janet W. Rich-Edwards, ScD,2,3 Chloe A. Zera, MD, MPH,4
Thomas F. McElrath, MD, PhD,4 and Ellen W. Seely, MD5
Abstract
Background: We designed and tested the validity of a questionnaire to characterize maternal recall of preg-
nancy complications associated with increased future cardiovascular disease risk, based on the 2011 American
Heart Association (AHA) guidelines.
Methods: A maternal recall questionnaire of pregnancy history was administered to 971 patients who had
participated in a previous cohort study of 1,608 pregnant women. Medical records from the study pregnancy
served as the gold standard. Prevalence, sensitivity (sens), specificity (spec), positive predictive value (PPV),
negative predictive value (NPV), and/or Spearman’s correlation coefficients (r) were calculated for each
question.
Results: A total of 526 (54%) individuals recontacted responded. Respondents were more likely to be older,
white, educated, and nulliparous and were less likely to deliver low-birthweight infants in the study pregnancy
than were individuals who did not respond. Mean length of recall was 4.35 years (standard deviation [SD] 0.46)
postpartum. Maternal recall was most accurate for gestational diabetes (sens: 92%, spec: 98%, PPV: 79%, NPV:
99%), infant birthweight (r= 0.95), and gestation length (r= 0.85). Maternal recall was modest for preeclampsia
(sens: 79%, spec: 97%, PPV: 68%, NPV: 98%) and pregnancy-associated hypertension, including preeclampsia
or gestational hypertension (sens: 60%, spec: 95%, PPV: 64%, NPV: 94%).
Conclusions: This validation study demonstrated that the majority of women could accurately recall a history
of gestational diabetes, infant birthweight, and gestational age at delivery, 4 years postpartum on average.
Recall of preeclampsia and pregnancy-associated hypertension overall was modest. Maternal report of these
pregnancy conditions may help clinicians identify women at increased risk for cardiovascular disease.
Introduction
Pregnancy complications, including gestational dia-betes,1–5 hypertension in pregnancy,6–10 low birth-
weight,11–13 and preterm delivery,12,14 are risk factors for
developing cardiovascular disease (CVD) later in life.15–18
The 2011 American Heart Association (AHA) ‘‘Guidelines
for the Prevention of Cardiovascular Disease in Women’’
recommended that healthcare providers take a history of
these pregnancies to identify women whose pregnancy his-
tory places them at increased risk for future CVD.19 How-
ever, there is a paucity of data regarding which questions
should be asked to solicit pregnancy complication history and
whether a woman’s response accurately reflects her preg-
nancy history.20
We designed and evaluated the validity of a brief ques-
tionnaire for maternal recall of pregnancy complications as-
sociated with increased future CVD risk, including gestational
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diabetes, preeclampsia, gestational hypertension, low infant
birthweight, and preterm birth.
Materials and Methods
A questionnaire was designed based on a review of the
maternal recall literature on gestational diabetes,21 pre-
eclampsia,22,23 birthweight,24–26 and gestational age at de-
livery.26–35 The questionnaire was piloted among the first 10
patients scheduled on a given day in both a general obstetrics
and a maternal fetal medicine practice who agreed to com-
plete the survey. A research assistant interviewed each pa-
tient following completion of the survey, recording feedback
to refine the questionnaire accordingly. The pilot and final
surveys were approved by the Institutional Review Board for
Brigham and Women’s Hospital at Partners Healthcare in
Boston, MA.
The questionnaire (Fig. 1) asked about each pregnancy
complication in a number of ways in order to identify a
smaller set of best-performing questions, which were deter-
mined by a joint review of all test statistics for each question
relative to the other questions. The surveywas administered to
patients who agreed to be contacted for future research after
participating in an earlier pregnancy study at Brigham and
Women’s Hospital.36 Briefly, the earlier study was a cohort
study of pregnant women (n= 1,608), initiating prenatal care
between October 2006 and February 2009 to test the utility of
angiogenic markers for predicting preeclampsia.36 Patients
FIG. 1. Maternal recall questionnaire.
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were eligible for inclusion if they were at least 18 years of age
and less than 16 weeks pregnant. The earlier study was ap-
proved by the Institutional Review Board at Partners
Healthcare. The current survey queried patients regarding the
pregnancy captured in the earlier study, since this was the
pregnancy for which we had complete data.
For the current study, gestational diabetes mellitus (GDM)
was defined by either clinical criteria (‘‘gestational diabetes’’
written in patient’s chart by a clinical provider) or laboratory
criteria ( ‡ 2 abnormal values on 100 g glucose tolerance test
using Carpenter Coustan criteria).37,38 Women with pre-
existing Type 1 or Type 2 diabetes, confirmed by medical
record review, were excluded from the primary analysis for
GDM.
Preeclampsia was defined by new-onset hypertension
(systolic blood pressure [SBP] ‡ 140mm Hg or diastolic
blood pressure [DBP] ‡ 90mm Hg on two occasions ‡ 6
hours apart) and proteinuria ( > 300mg in 24 hours or a
protein-to-creatinine ratio > 0.20 when a 24-hour urine was
not available) after 20 weeks of pregnancy.36 Superimposed
preeclampsia was diagnosed if a woman had chronic hyper-
tension (SBP ‡ 140mm Hg or DBP ‡ 90mm Hg) that pre-
dated pregnancy or was present before 20 weeks with
worsening hypertension and new-onset proteinuria, as pre-
viously defined. Gestational hypertensionwas defined as new-
onset hypertension (SBP ‡ 140mm Hg or DBP ‡ 90mm Hg)
on two occasions at least 6 hours apart without protein-
uria after 20 weeks of pregnancy.36 As ‘‘pregnancy-induced
hypertension’’ was included without definition in the AHA
guidelines, we defined it in this study as pregnancy-associated
hypertension, including gestational hypertension or pre-
eclampsia. Women with chronic hypertension were excluded
from the primary analyses for preeclampsia and pregnancy-
associated hypertension. Sensitivity analyses includedwomen
with preexisting chronic hypertension and expanded the
medical record definition of both preeclampsia and pregnancy-
associated hypertension to additionally include superimposed
preeclampsia.
Infant birthweight was obtained from the delivery record.
Preterm delivery was defined as delivery prior to 37 weeks
gestational age. Patients had an ultrasound prior to 15 weeks
as part of the protocol for the earlier study. Gestational age
was calculated by last menstrual period (LMP) if the first-
trimester ultrasound confirmed the due date within 7 days or
if the second-trimester ultrasound was consistent with LMP
dating within 10 days. If ultrasound dating was more than 7 or
10 days different, respectively, from the due date obtained
from LMP, the pregnancy was redated according to the ear-
liest ultrasound available.39
Potential respondents were initially contacted by letter and
e-mail, if available. Each patient was given a unique identifier
number at the initial point of contact to match her responses
to her pregnancy data. The letter gave patients the option to
complete an online survey, an enclosed paper survey returned
in a prepaid envelope, or a blank survey returned with only
their unique identifier to opt out of the study. The e-mail gave
patients the option of clicking a link to an online survey or
simply clicking replying (without text) to opt out. A trained
research assistant called patients who did not reply to the
initial letter/e-mail or opt out of the study. An IRB-approved
script was used to administer the questionnaire by phone.
Patients who still did not complete the letter/e-mail/phone
survey or opt out of the study received a second e-mail or
letter, respectively. Study data were collected and managed
using Research Electronic Data Capture (REDCap), initiated
at Vanderbilt University (Nashville, TN) by a consortium of
institutions. This secure Health Insurance Portability and
Accountability Act (HIPAA)-compliant electronic data cap-
ture tool was hosted at Brigham and Women’s Hospital.40
The Student’s t-test was used to compare the demo-
graphics of the earlier study’s patients who agreed to be
contacted for future studies versus those who did not and for
respondents versus nonrespondents to the questionnaire for
the current study. Medical records from the study pregnancy
served as the gold standard. Prevalence of the given condi-
tion, pretest probability, sensitivity, specificity, positive
predictive value (PPV), and negative predictive value (NPV)
were calculated for all questions pertaining to GDM, pre-
eclampsia, and pregnancy-associated hypertension overall.
Sensivity represents the percentage of women who correctly
indicated the condition on the questionnaire, among those
with the condition; specificity is the percentage who cor-
rectly indicated on the questionnaire that they did not have
the condition, among those who did not have the condition.
The PPV is the proportion of accurate positive maternal re-
call according to the medical record; the NPV is the pro-
portion of accurate negative maternal recall according to
the medical record. Spearman correlation coefficients were
calculated for questions regarding infant birthweight and
gestational length. Completion rates were calculated for all
survey questions.
Stratified analyses for potential confounding variables
were performed. A Mantel-Haenszel analysis was used to
stratify answers to questions by length of time from delivery
to recall.
Results
There were no significant differences between the 971
patients who agreed to be recontacted after the earlier study
and the 365 who did not with regard to age, parity, education,
race, or any pregnancy condition of interest. The overall re-
sponse rate was 54% (n= 526). Of these respondents, 61%
responded by mail, 23% online, and 17% by phone. Mean
length of recall was 4.35 years (standard deviation [SD] 0.46)
postpartum. Twenty-one of the 971 women we attempted to
contact were not reachable by mail, e-mail, or phone. Eleven
patients actively opted out of the study.
Respondents were more likely to be older, nulliparous,
Caucasian, and more highly educated than non-respondents
(Table 1). There were no significant differences between
respondents and non-respondents with regard to the presence
of GDM, preeclampsia, or gestational age at delivery; how-
ever, non-respondents were more likely to deliver low
birthweight infants (13% vs. 7%).
Gestational diabetes
In our sample, 7.4% of women (n = 39) had GDM, ac-
cording to medical records. Table 2 shows the test charac-
teristics for five questions regarding history of GDM. All
questions had high specificity and NPV, varying from 96% to
nearly 100% for both. Question 1 (‘‘Did you have gestational
diabetes?’’) had a sensitivity of 92%, indicating that this
question captured the vast majority of record-defined cases.
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However, 79% of women who answered yes to this question
had medical record evidence of having had GDM (PPV).
Question 2a (‘‘During [the study] pregnancy, did you have to
do home fingerstick blood monitoring?’’) had a similar sen-
sitivity to that of question 1, with a slightly lower PPV of
77%. Question 2d (‘‘Did you have diabetes of pregnancy?’’)
had lower sensitivity (85%) but a slightly higher PPV at 83%.
Question 2b (‘‘Did you have to take medicine to regulate your
blood sugar [including insulin]?’’) and question 2c (‘‘Did you
have high blood sugar?’’) performed less well in terms of
sensitivity; question 2b had a 95% PPV, the highest of all the
GDM items tested.
Table 1. Demographic and Pregnancy Characteristics of Survey Respondents and Non-respondents








Age at study pregnancy (years)* 954 32.1 (5.7) 519 33.0 (5.0) 435 31.1 (6.2)
Gestational age (weeks) 971 38.5 (2.3) 526 38.6 (2.1) 445 38.4 (2.5)
Birthweight (grams)*,a 932 3,244 (635) 487 3,301 (578) 445 3,183 (687)
Nulliparous* 419 43.2 245 46.6 174 39.1
Education*
Less than high school 36 3.8 5 1.0 31 7.1
High school graduate 92 9.6 34 6.6 58 13.3
Technical school 142 14.9 47 9.1 95 21.7
Some college 308 32.2 188 36.2 120 27.5
College graduate 378 39.5 245 47.2 133 30.4
Race/Ethnicity*
White 619 63.7 388 73.8 231 51.9
African American 126 13.0 47 8.9 79 17.8
Asian 56 5.8 27 5.1 29 6.5
Hispanic 119 12.3 47 8.9 72 16.2
Other 51 5.3 17 3.2 34 7.6
Singleton 909 93.6 488 92.8 421 94.6
Chronic hypertension 59 6.1 33 6.3 26 5.8
Gestational hypertensionb 49 5.0 24 4.6 25 5.6
Preeclampsiac 78 8.0 38 7.2 40 9.0
Superimposed preeclampsia 21 2.2 12 2.3 9 2.0
Diabetesd 28 2.9 17 3.2 11 2.5
Gestational diabetes 77 7.9 39 7.4 38 8.5
Preterm ( < 37 weeks) 152 15.7 78 14.8 74 16.6
Low birthweight (< 2,500 g)* 91 9.8 35 7.2 56 12.6
aSingleton births only.
bNot including preeclampsia.
cThe seven respondents with HELLP also had preeclampsia and are included among the n = 38.
dIncludes types 1 and 2.
*p < 0.05 comparing respondents to non-respondents.
HELLP, hemolysis, elevated liver enzymes, low platelets; SD, standard deviation.




















1. During the study pregnancy,
did you have gestational diabetes?
Yes 34 9 7.4 91.9 98.1 79.1 99.3
No 3 452
2. During that pregnancy, did you have:
A. To do home fingerstick
blood sugar monitoring?
Yes 36 11 7.8 92.3 97.6 76.6 99.3
No 3 453
B. To take medicine to regulate
your blood sugar (including insulin)?
Yes 18 1 7.6 47.4 99.8 94.7 95.9
No 20 464
C. High blood sugar? Yes 25 16 7.6 65.8 96.6 61.0 97.2
No 13 448
D. Diabetes of pregnancy? Yes 33 7 7.7 84.6 98.5 82.5 98.7
No 6 458
GDM, gestational diabetes mellitus; NPV, negative predictive value; PPV, positive predictive value.
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Preeclampsia
In our sample, 7.2% of women (n= 38) had medical record
evidence of preeclampsia. The performance of questions for
preeclampsia is shown in Table 3. Specificity and NPV for all
questions pertaining to preeclampsia were high, ranging from
93% to 100% for specificity and from 92% to 99% for NPV.
The primary question used to obtain maternal report of pre-
eclampsia was question 5 (‘‘During that pregnancy, did you
have preeclampsia, eclampsia, pregnancy-induced hyper-
tension, or toxemia?’’) (Fig. 1). Women responded by
checking the box(es) next to the condition(s) they had or by
checking a box to indicate none. When positive maternal
report of preeclampsia was defined as checking any of the
conditions (5b–5e), the sensitivity for preeclampsia was 84%
and PPV was 56%. When positive maternal report of pre-
eclampsia was alternatively defined as indicating ‘‘Yes, I had
preeclampsia,’’ regardless of their responses to eclampsia,
pregnancy-induced hypertension, or toxemia, specificity
(97%) and PPV (68%) improved, sensitivity decreased to
79%, and NPV remained unchanged (Table 3).
We also evalauted combinations of well-performing
questions to determine whether these improved the test
characteristics, relative to a single question for preeclampsia.
When we defined positive maternal report of preeclampsia as
saying ‘‘Yes, I had preeclampsia’’ to question 5 and ‘‘Yes’’ to
‘‘During that pregnancy, did you have high protein in your
urine?’’ (question 6), the PPV for preeclampsia improved
from 68% to 78%. However, this improvement in PPV was at
the cost of a loss in sensitivity, which dropped from 79% to
55%. Since low birthweight and preterm birth can be con-
sequences of a preeclamptic pregnancy, we additionally
validated maternal report of (1) preeclampsia and low
birthweight, (2) preeclampsia and preterm birth, and (3)
preeclampsia, low birthweight, and preterm birth against
medical record evidence of preeclampsia. The PPVs for these
combinations were 100%, 77%, and 100%, respectively, with
concomitant decreases in sensitivity to less than 35%. The
absolute number of women who reported both low birth-
weight and preeclampsia was small (n = 6), and the comple-
tion rate decreased when multiple maternal responses were
required. Additional preeclampsia analyses including pa-
tients with chronic hypertension (thereby capturing super-
imposed preeclampsia) showed similar results (data not
shown).
Pregnancy-associated hypertension
Sixty-two women (12%) had medical record evidence of
pregnancy-associated hypertension (preeclampsia or gesta-
tional hypertension). The best-performing single question for
pregnancy-associated hypertension was ‘‘During the study
pregnancy, did you have high blood pressure or hyper-
tension?’’ (60% sensitivity, 95% specificity, 64% PPV,
and 94% NPV) (Table 4, question 4). A higher PPV of 71%
for pregnancy-associated hypertension was observed for
the combined response of ‘‘No’’ to question 3 (‘‘Did you
have high blood pressure [hypertension] before the study
pregnancy?’’) plus a response to question 5 (‘‘During that
pregnancy, did you have preeclampsia, eclampsia, pregnancy-
induced hypertension, or toxemia?’’) of ‘‘Yes, I had
pregnancy-induced hypertension’’ (response B) or ‘‘Yes, I
had preeclampsia’’ (response D). This combination resulted
in a lower sensitivity (53%), higher specifitity (97%), and
slightly lower NPV (93%) (Table 4). Additional analyses
including patients with chronic hypertension (thereby cap-
turing superimposed preeclampsia) showed similar results
(data not shown).
Birthweight
In our sample, 7.2% (n= 35) of the women delivered a low-
birthweight infant during the study pregnancy. Women were
asked about the birthweight of their child in three ways. The
vast majority of women completed all three items: 94%
completed the free-text response (in pounds and ounces or
grams; question 7), 100% the ‘‘small, medium, or large’’ item
(question 8), and 99% the categorical question (question 9).
Table 5 shows the mean differences and Spearman correla-
tion coefficients, comparing maternal recall of birthweight
using free text to that recorded in the medical record. Mothers
were accurate in their recall of infant birthweight, with small
mean differences and a correlation coefficient of 0.95.
Comparing the midpoints (assigning birth weight < 1,500 g
to the smallest and > 4,000 g to the largest open-ended ca-
tegories) of the four birthweight categories (question 9)
against medical record birthweight yielded a correlation co-
efficient of 0.85 ( p < 0.0001). Although both free-text and
categorical birthweight questions performed well, the free-
text option seemed to generate a more accurate response.
However, 29 (5%) more patients answered the categorical
question than the free-text question, representing the only
question in the survey showing a discrepancy in the number
of patients answering one of the questions among a group of
questions for a given condition.
Figure 2 shows a linear relationship between medical-
record-documented birthweight and free-text maternal recall
of birthweight. The figure also differentiates patients who
categorized their babies as small, medium, or large. In re-
sponse to the accompanying question (‘‘How did you choose
this category?’’), most patients stated that their rationale was
based on comparison to other children or in response to
comments made by healthcare providers. A Bland-Altman
plot analysis showed no consistent bias or pattern of under-
estimating/overestimating infant birthweight in maternal re-
call (data not shown).
Gestational length
In our sample, 14.8% (n = 78) of the women delivered
preterm in the study pregnancy. Table 5 shows the mean
differences and Spearman correlation coefficients for ma-
ternal recall of gestation length using free text (question 10)
and categories (question 11), compared to the medical record.
To create a continuous variable from the categorical response
to question 11 (‘‘Did you deliver before, on, or after your due
date?’’), 40 weeks was assigned to those selecting the re-
sponse ‘‘within one week of my due date.’’ For individuals
selecting one of the other responses, the number of weeks
early or late was subsequently scaled, subtracting from or
adding to 40 weeks gestation. Table 5 shows that, with regard
to gestation length, both question 10 (‘‘How many weeks
pregnant were you when you delivered?’’) and question 11
(‘‘Did you deliver before, on or after your due date?’’)
achieved Spearman correlation coefficients of 0.85 compared
to medical record gestation length. Question 10 (‘‘Howmany
706 CARTER ET AL.






















4. During the study pregnancy, did
you have high blood pressure
or hypertension?
Yes 27 31
11.9 71.1 93.3 46.6 97.4
No 11 419
5. During that pregnancy, did you have preeclampsia, eclampsia, pregnancy-induced hypertension, or toxemia?
Response B, C, D, or E:
B. Yes, I had preeclampsia.
C. Yes, I had eclampsia.
D. Yes, I had pregnancy-
induced hypertension.
E. Yes, I had toxemia.
Yes 32 25
11.7 84.2 94.4 56.1 98.6
No 6 424
Response B, C, or E:
B. Yes, I had preeclampsia.
C. Yes, I had eclampsia.
E. Yes, I had toxemia.
Yes 30 14
9.0 79.0 96.9 68.2 98.2
No 8 435
Response B:
Yes, I had preeclampsia.
Yes 30 14
9.0 79.0 96.9 68.2 98.2No 8 435
Response C:
Yes, I had eclampsia.
Yes 0 1
0.2 — 99.8 — 92.2No 38 448
Response D:
Yes, I had pregnancy-induced hypertension.
Yes 7 12
3.9 18.4 97.3 36.8 93.4No 31 437
Response E:
Yes, I had toxemia.
Yes 0 1
0.2 — 99.8 — 92.2No 38 448
6a. During that pregnancy, did you have:
High protein in the urine?
Yes 24 21
9.2 63.2 95.3 53.3 96.8No 14 429
Seizures or convulsions?
Yes — — — —
100.0 — 92.2No 38 449
5. During that pregnancy, did you
have preeclampsia, eclampsia, pregnancy-
induced hypertension, or toxemia?
Yes, I had preeclampsia.
AND
6. During that pregnancy, did you have
high protein in the urine?
Yes.
Yes 21 6
5.5 55.3 98.7 77.8 96.3
No 17 443
5. During that pregnancy, did you have
preeclampsia, eclampsia, pregnancy-
induced hypertension, or toxemia?




1.4 21.4 100.0 100.0 95.0No 22 415
5. During that pregnancy, did you have
pre-eclampsia, eclampsia, pregnancy-
induced hypertension or toxemia?




3.5 34.2 99.1 76.5 94.6
No 25 439
5. During that pregnancy, did you have
Preeclampsia, eclampsia, pregnancy-
induced hypertension, or toxemia?






1.4 21.4 100.0 100.0 94.9No 22 410
aLow birthweight is defined as maternal report of < 2,500 grams or < 5 pounds and 8 ounces in response to question 7: ‘‘What was the
birthweight of that baby (in pounds and ounces or grams)?’’
bPreterm birth is defined as maternal report of < 37 weeks gestation in response to question 10: ‘‘How many weeks pregnancy were you
when you delivered?’’
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4. During the study pregnancy, did you have high blood pressure or hypertension?
Yes 37 21
11.9 59.7 95.1 63.8 94.2No 25 405
AND
3. Did you have high blood
pressure (hypertension)
before the study pregnancy?
No.
Yes 31 17
9.9 50.8 96.0 64.6 93.1
No 30 407
5. During that pregnancy, did you have preeclampsia, eclampsia, pregnancy-induced hypertension, or toxemia?
Yes, I had pregnancy-
induced hypertension.
Yes 10 9
3.9 16.1 97.9 52.6 88.9No 52 416
AND





2.9 13.1 98.6 57.1 88.7
No 53 417
3. Did you have high blood
pressure (hypertension)
before the study pregnancy?
No.
AND
4. During the study pregnancy,




5. During that pregnancy, did you have
preeclampsia, eclampsia, pregnancy-
induced hypertension, or toxemia?
Yes, I had preeclampsia.
Yes 37 23
12.5 60.7 94.5 61.7 94.3
No 24 396
3. Did you have high blood
pressure (hypertension)
before the study pregnancy?
No.
AND
5. During that pregnancy,
did you have preeclampsia,
eclampsia, pregnancy-induced
hypertension, or toxemia?
Yes, I had pregnancy-
induced hypertension.
OR
Yes, I had preeclampsia.
Yes 32 13
9.4 52.5 96.9 71.1 93.3
No 29 406
3. Did you have high blood
pressure (hypertension)
before the study pregnancy?
No.
AND
4. During the study pregnancy,




5. During that pregnancy, did you have
preeclampsia, eclampsia, pregnancy-
induced hypertension, or toxemia?
Yes, I had pregnancy-
induced hypertension.
OR
Yes, I had preeclampsia.
Yes 37 23
12.5 60.7 94.5 61.7 94.3
No 24 396
Medical record evidence of pregnancy-associated hypertension (gestational hypertension or preeclampsia) is defined as nonproteinuric or
proteinuric new-onset high blood pressure (SBP ‡ 140mm Hg or DBP ‡ 90mm Hg).
DBP, diastolic blood pressure; SBP, systolic blood pressure.
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weeks pregnant were you when you delivered?’’) performed
better among preterm mothers, and both questions had a
similar number of patient responses.
Additional analyses
Since this cohort tended to be older, with a mean maternal
age of 33 (SD 5) years, and was highly educated (47% college
graduates), we did a stratified analysis of the best-performing
questions (bolded in Fig. 1) by age and education, using a
Pearson correlation coefficient for continuous variables and a
Breslow-Day test for homogeneity of odds ratios for cate-
gorical variables. An analysis of the youngest quartile of
patients, who were less than or equal to 25 years of age,
compared to those greater than 25, showed no difference in
patient response to the questions for GDM, preeclampsia,
pregnancy-associated hypertension, birthweight, or gesta-
tional length. Similarly, a comparison of patients stratified by
college degree showed no difference in correct responses to
questions for any outcome of interest.
A Mantel-Haenszel analysis of the best-performing ques-
tions for each pregnancy outcome of interest stratified by
length of time between delivery and recall (using the median
time of 3.6 years as the cutpoint) showed no difference in
maternal recall by time since delivery.
Discussion
In this study, we validated questions for maternal recall of
pregnancy complications, predictive of future cardiovascular
outcomes. We found that, on average, 4 years after preg-
nancy, several methods of querying GDM, birthweight, and
Table 5. Mean Difference and Spearman Correlation Coefficients, Comparing Birthweight











Question 7: ‘‘What was the birth weight of that baby?’’
Overall n= 477 3,306 – 599 3,301 – 582 4– 166 0.95
Among LBW mothers ( < 2,500 g) n = 35 1,949 – 555 1,981 – 485 - 32– 256 0.92
Among non-LBW mothers ( ‡ 2500 g) n = 442 3,413 – 455 3,406 – 445 7– 157 0.93
Question 10: How many weeks pregnant were you when you delivered?
Overall n= 503 39 – 2 39 – 2 0– 1 0.85
Among preterm mothers ( < 37 weeks) n = 73 35 – 3 35 – 2 0– 2 0.82
Among non–preterm mothers ( ‡ 37 weeks) n = 430 39 – 1 39 – 1 0– 1 0.78
Question 11: Did you deliver before, on, or after your due date?
Overall n= 518 39 – 4 39 – 2 0– 3 0.85
Among preterm mothers ( < 37 weeks) n = 78 35 – 3 35 – 2 0– 2 0.82
Among non–preterm mothers ( ‡ 37 weeks) n = 440 39 – 3 39 – 1 0– 3 0.78
aMean difference is relative to the medical record (gold standard) value, where difference =maternal report – medical record value.
LBW, low birthweight.
FIG. 2. Maternal recall of birth-
weight and infant size vs. medical
record birthweight.
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gestational length produced a high degree of accuracy as
determined by high sensitivity/specificity/NPV and moderate
PPV for GDM and high correlation coefficients for birth-
weight and gestational length. Although maternal recall of
preeclampsia alone and pregnancy-associated hypertension
overall were specific and yielded good NPVs, the recalls
demonstrated modest sensitivities and PPVs.
The terminology ‘‘pregnancy-induced hypertension
(PIH)’’ rather than ‘‘gestational hypertension’’ was used in
the questionnaire, as it was thought to be the term most
commonly used clinically at the time study patients deliv-
ered. However, for this group of women, who delivered be-
tween 2006 and 2009, ‘‘pregnancy-induced hypertension’’
performed poorly as a measure of gestational hypertension,
preeclampsia, and pregnancy-associated hypertension over-
all. Similarly, asking women about ‘‘toxemia’’ was neither
sensitive nor had a high PPV for preeclampsia. Instead, the
best measure of preeclampsia came from asking a woman
whether she had ‘‘preeclampsia.’’ However, even this ques-
tion would detect only 79% (sensitivity) of women who had a
history of preeclampsia in a clinical practice. In our study
population, only 68% (PPV) of women who reported pre-
eclampsia were accurate, according to medical records. The
fact that maternal recall of pregnancy-associated hyperten-
sion appears to be less accurate than other pregnancy com-
plications likely reflects multiple sources of error, including
poor clinician-patient communication or poor maternal re-
call, which may be significantly improved with better patient
education about key obstetrical events.41
If the goal of obtaining a patient history is to confirm
preeclampsia in an individual, the physician will likely pri-
oritize a high PPV (i.e., having a higher probability that the
individual reporting preeclampsia truly has it) over a high
sensitivity, which represents the likelihood that a true pre-
eclamptic is able to report it. In that case, the addition of
‘‘high protein in the urine’’ to maternal report of ‘‘pre-
eclampsia,’’ with an increase in PPV from 68% to 78%,
might be the physician’s best option to feel confident about a
maternal report from an individual patient. However, if the
physician is looking to capture as much of the true pre-
eclampsia patient population as possible, the sensitivity
should be priorizited over the PPV; as such, it may be best to
stick with the single question about preeclampsia, given the
resultant drop in sensitivity from 79% to 55% with the ad-
dition of the proteinuria question. This example illustrates a
tradeoff between a broad capture of a population at risk
versus precision with a given patient.
In addition to preeclampsia, the AHA recognizes
pregnancy-induced hypertension (presumably gestational
hypertension with or without preeclampsia/proteinuria) as a
marker of cardiovascular risk. Within this study, we were
able to evaluate various combinations of questions regarding
hypertension to detect this more inclusive category of preg-
nancy-associated hypertension. Although no particular
combination of questions was clearly superior to another, it
does appear that combined maternal responses may outper-
form the validity of an individual question to detect preg-
nancy-associated hypertension. For example, a question
ruling out chronic hypertension improved the PPV of indi-
vidual questions about preeclampsia and hypertension in
pregnancy to detect medical record pregnancy-associated
hypertension.
We attempted to design and validate a maternal recall
questionnaire to capture multiple pregnancy complications
associated with cardiovascular risk. Previous literature has
reported on maternal recall of a single pregnancy complica-
tion. The ability of women to accurately recall history of
gestational diabetes has been documented previously by
Hosler et al. using the New York State Pregnancy Risk As-
sessment Monitoring System (PRAMS).21 At 2–6 months
after delivery, there was a 93.8% agreement with a kappa of
0.53 for maternal report of ‘‘high blood sugar (diabetes)’’
during pregnancy and birth certificate record of gestational
diabetes. Although their study did not assume a gold stan-
dard, our study used medical records as the gold standard and
found maternal report of GDM to be both valid (sensitivity
92%) and accurate (PPV 79%) with longer maternal recall.
A review of the literature on maternal recall of pregnancy-
associated hypertension found low sensitivity, with estimates
ranging from 57% to 87% and consistently high specificity
( > 90%), similar to our study.42 Diehl et al.23 obtained the
best validity estimates from a six-question survey of pre-
eclampsia, reporting 80% sensitivity, 96% specificity, 51%
PPV, and 99% NPV, after a mean recall of 27 years. We
found strikingly similar test characteristics—79% sensitivity,
97% specificity, 68% PPV, and 98% NPV—for the single
item ‘‘Did you have preeclampsia?’’ recalled an average of 4
years after pregnancy. It is possible that the single question
regarding preeclampsia performs better among more recent
pregnancies, perhaps due to more consistent clinician use of
the word ‘‘preeclampsia’’ with today’s mothers.
Two studies assessed related pregnancy outcomes of
birthweight and preterm delivery in the same population.
Little et al. conducted a validation study among 377 women
in aWashington State health maintenance organization. They
reported greater than 90% agreement when asking women to
recall infant birthweight and greater than 80% agreement
with regard to gestational length, compared to hospital and
birth certificate records.26 In the other study, Dutch re-
searchers demonstrated small but statistically significant
mean differences in recalled birthweight and gestational age
after 10–12 years: 25 grams for birthweight and 0.6 days for
gestational age.25
Our study had several limitations that should be considered
when interpreting the results. The women in this cohort were
questioned 3 to 6 years after the reference pregnancy. It is
unclear how well these questions would perform in a popu-
lation further removed from pregnancy. However, a review of
10 maternal recall papers on preeclampsia did not find a
consistent effect of recall length from pregnancy on accuracy
of maternal report.42 With regard to generalizability, women
who responded to the questionnaire were more likely to be
educated and Caucasian than were nonrespondents; however,
a stratified analysis in our study population suggested that this
did not alter the results. Furthermore, the study population
came from a single tertiary referral center with a higher
prevalence of the pregnancy complications than is seen in the
general public. The predictive values of the items will depend
on the prevalence of the underlying condition in a population.
In our sample, the prevalence of GDM (7.4%) and pre-
eclampsia (7.2%) was higher than it may be in other popu-
lations, driving the predictive value of a positive maternal
recall higher and the predictive value of a negative maternal
recall lower than might be observed elsewhere. In particular,
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the PPV for preeclampsia, already modest in this setting at 68%
for the best-performing question, would be expected to be lower
still where the prevalence of preeclampsia is less than 7%.
Important strengths of this study include the large sample
size of 526 women and asking about each pregnancy com-
plication of interest in multiple ways to determine best-
performing questions in a constant population of patients. We
took this one step further by comparing the completion rate of
questions in each category, since a high correlation coeffi-
cient for a questionmay not matter if patients are less likely to
answer the open-ended question because they are unsure of
the exact response value. We performed subgroup analyses,
not typically conducted in previous studies, looking among
patients with preexisting diabetes, gestational hypertension,
superimposed preeclampsia, and the extremes of birthweight
and gestational age.
Current strategies for women with a history of hyperten-
sive pregnancy include counseling and increased monitoring
of modifiable risk markers (i.e., blood pressure, cholesterol)
are benign and relatively inexpensive. When the cost of
‘‘treating’’ someone at risk for CVD does not have major
negative side effects, a low PPV, such as that seen for pre-
eclampsia, should not preclude the clinician from obtaining
pregnancy history and initiating a risk-reduction plan where
appropriate. Maximizing sensitivity to capture a broad pop-
ulation at heightened CVD risk, even at the cost of PPV, may
better serve the goal of preventing CVD.
In summary, if a woman says that she did not have a
pregnancy complication, the consistently high specificity and
NPVs observed in this study indicate that her self-report is
very likely to be accurate. Similarly, women seem able to
recall GDM, gestation length, and birthweight accurately,
whereas maternal recall of pregnancy-associated hyperten-
sion is less so. Surveys such as this one may prove useful
indicators of a parous woman’s cardiovascular risk. The best-
performing questions from our study (see Fig. 1, bolded
items) may form a foundation to help clinicians elicit a fo-
cused history of GDM, preeclampsia, pregnancy-associated
hypertension, preterm birth, and infant birthweight.
Conclusions
This study demonstrates the validity of maternal recall of
important pregnancy events by defining parameters including
sensitivity, specificity, PPV, NPV, and correlation coeffi-
cients for questions concerning pregnancy complications
associated with increased risk of future CVD. A validated
survey instrument is crucial to help clinicians elicit the
pregnancy history recommended by the AHA19 in order to
identify and address a woman’s cardiovascular risk factors
and, hopefully, improve her lifetime disease trajectory.
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